| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 110 | 2023 | 2332 | 10.340 |
Why?
|
| Islets of Langerhans Transplantation | 90 | 2024 | 743 | 8.910 |
Why?
|
| Graft Survival | 102 | 2024 | 3843 | 5.080 |
Why?
|
| Transplantation Tolerance | 24 | 2022 | 620 | 4.960 |
Why?
|
| Organ Preservation | 23 | 2024 | 382 | 4.060 |
Why?
|
| Kidney Transplantation | 44 | 2024 | 4242 | 3.670 |
Why?
|
| Perfusion | 25 | 2024 | 1390 | 3.350 |
Why?
|
| Graft Rejection | 54 | 2024 | 4481 | 2.960 |
Why?
|
| Tissue Donors | 54 | 2023 | 2335 | 2.810 |
Why?
|
| Transplantation, Heterologous | 39 | 2024 | 2381 | 2.710 |
Why?
|
| Islets of Langerhans | 36 | 2023 | 1342 | 2.540 |
Why?
|
| Tissue and Organ Procurement | 26 | 2022 | 963 | 2.490 |
Why?
|
| Immunosuppressive Agents | 34 | 2024 | 4190 | 2.430 |
Why?
|
| T-Lymphocytes, Regulatory | 24 | 2024 | 3092 | 2.260 |
Why?
|
| Immune Tolerance | 30 | 2022 | 2307 | 2.230 |
Why?
|
| Living Donors | 21 | 2024 | 643 | 2.000 |
Why?
|
| Organ Transplantation | 14 | 2023 | 1165 | 1.990 |
Why?
|
| Reperfusion Injury | 8 | 2024 | 1026 | 1.980 |
Why?
|
| Liver | 38 | 2024 | 7512 | 1.800 |
Why?
|
| Diabetes Mellitus, Type 1 | 36 | 2022 | 3417 | 1.800 |
Why?
|
| Pancreas Transplantation | 14 | 2018 | 197 | 1.760 |
Why?
|
| Transplantation, Homologous | 51 | 2023 | 4822 | 1.570 |
Why?
|
| Carcinoma, Hepatocellular | 16 | 2023 | 2293 | 1.470 |
Why?
|
| Transplants | 3 | 2022 | 206 | 1.440 |
Why?
|
| Isoantigens | 5 | 2016 | 559 | 1.370 |
Why?
|
| Organ Preservation Solutions | 5 | 2021 | 100 | 1.350 |
Why?
|
| Insulin-Secreting Cells | 12 | 2022 | 898 | 1.340 |
Why?
|
| Liver Failure | 9 | 2018 | 250 | 1.320 |
Why?
|
| Waiting Lists | 19 | 2020 | 766 | 1.300 |
Why?
|
| Liver Neoplasms | 16 | 2023 | 4310 | 1.170 |
Why?
|
| Kidney | 17 | 2024 | 7033 | 1.140 |
Why?
|
| Alloys | 2 | 2018 | 110 | 1.130 |
Why?
|
| Antilymphocyte Serum | 10 | 2024 | 491 | 1.090 |
Why?
|
| Skin Transplantation | 16 | 2013 | 1091 | 1.080 |
Why?
|
| End Stage Liver Disease | 6 | 2023 | 352 | 1.040 |
Why?
|
| Titanium | 2 | 2018 | 490 | 0.940 |
Why?
|
| Swine | 21 | 2024 | 5909 | 0.930 |
Why?
|
| Kidney Failure, Chronic | 12 | 2024 | 2478 | 0.890 |
Why?
|
| Tacrolimus | 3 | 2023 | 736 | 0.870 |
Why?
|
| T-Lymphocytes | 35 | 2024 | 10203 | 0.860 |
Why?
|
| Diabetes Mellitus, Experimental | 26 | 2022 | 1116 | 0.830 |
Why?
|
| Brain Death | 6 | 2023 | 357 | 0.810 |
Why?
|
| Blood Substitutes | 2 | 2019 | 57 | 0.810 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 1838 | 0.800 |
Why?
|
| Animals | 162 | 2024 | 168089 | 0.790 |
Why?
|
| Mice, Inbred BALB C | 29 | 2024 | 6200 | 0.760 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2024 | 4373 | 0.710 |
Why?
|
| Cold Ischemia | 5 | 2021 | 70 | 0.700 |
Why?
|
| Reoperation | 14 | 2018 | 4303 | 0.670 |
Why?
|
| B-Lymphocytes | 13 | 2021 | 4744 | 0.670 |
Why?
|
| Transplantation Immunology | 8 | 2013 | 537 | 0.660 |
Why?
|
| Receptors, Interleukin-2 | 5 | 2006 | 564 | 0.660 |
Why?
|
| Liver Failure, Acute | 2 | 2018 | 181 | 0.660 |
Why?
|
| Oxygen | 4 | 2019 | 4228 | 0.650 |
Why?
|
| Death | 6 | 2022 | 677 | 0.650 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2010 | 198 | 0.630 |
Why?
|
| Hemoglobins | 3 | 2019 | 1525 | 0.630 |
Why?
|
| Humans | 238 | 2024 | 761222 | 0.620 |
Why?
|
| Heat Stroke | 1 | 2018 | 29 | 0.620 |
Why?
|
| Silicates | 1 | 2018 | 47 | 0.610 |
Why?
|
| Lymphocyte Transfusion | 3 | 2015 | 232 | 0.600 |
Why?
|
| Temperature | 4 | 2020 | 2219 | 0.600 |
Why?
|
| Primates | 7 | 2023 | 521 | 0.600 |
Why?
|
| Relaxin | 1 | 2018 | 42 | 0.590 |
Why?
|
| Transplantation Chimera | 2 | 2019 | 594 | 0.590 |
Why?
|
| Mice, Inbred C3H | 14 | 2019 | 914 | 0.590 |
Why?
|
| Thymus Gland | 15 | 2011 | 1243 | 0.580 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2010 | 585 | 0.570 |
Why?
|
| Materials Testing | 2 | 2018 | 865 | 0.570 |
Why?
|
| Zirconium | 1 | 2018 | 108 | 0.570 |
Why?
|
| Portal Vein | 4 | 2015 | 432 | 0.560 |
Why?
|
| Nanocomposites | 1 | 2017 | 49 | 0.550 |
Why?
|
| Rats, Inbred Lew | 27 | 2019 | 1159 | 0.540 |
Why?
|
| Major Histocompatibility Complex | 10 | 1995 | 872 | 0.530 |
Why?
|
| Mice, Inbred C57BL | 42 | 2024 | 22128 | 0.520 |
Why?
|
| Mice | 79 | 2024 | 81330 | 0.520 |
Why?
|
| Lymphocyte Activation | 14 | 2022 | 5478 | 0.520 |
Why?
|
| Insulin | 21 | 2021 | 6588 | 0.510 |
Why?
|
| Transplantation | 4 | 2013 | 221 | 0.500 |
Why?
|
| Liver Diseases | 6 | 2015 | 1301 | 0.500 |
Why?
|
| Histocompatibility Antigens | 5 | 2008 | 467 | 0.480 |
Why?
|
| Hepatitis C | 9 | 2016 | 1579 | 0.470 |
Why?
|
| Adenosine Triphosphate | 4 | 2020 | 1988 | 0.470 |
Why?
|
| Hepatic Artery | 4 | 2015 | 232 | 0.470 |
Why?
|
| Heart Transplantation | 17 | 2024 | 3258 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 15 | 2017 | 9187 | 0.460 |
Why?
|
| Cyclosporine | 2 | 2016 | 776 | 0.460 |
Why?
|
| Warm Ischemia | 3 | 2020 | 58 | 0.450 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 322 | 0.440 |
Why?
|
| Chimerism | 2 | 2019 | 155 | 0.440 |
Why?
|
| Motivation | 1 | 2023 | 2002 | 0.430 |
Why?
|
| Biocompatible Materials | 3 | 2018 | 1683 | 0.420 |
Why?
|
| Retrospective Studies | 60 | 2023 | 80675 | 0.410 |
Why?
|
| Adenoviridae | 5 | 2011 | 1084 | 0.410 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2019 | 1803 | 0.400 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 31 | 0.400 |
Why?
|
| Cryopreservation | 6 | 2024 | 728 | 0.390 |
Why?
|
| Male | 123 | 2024 | 360703 | 0.380 |
Why?
|
| Autoimmunity | 7 | 2021 | 1356 | 0.380 |
Why?
|
| Travel | 2 | 2014 | 796 | 0.380 |
Why?
|
| Neurosurgery | 1 | 2018 | 679 | 0.380 |
Why?
|
| Postoperative Hemorrhage | 2 | 2014 | 416 | 0.370 |
Why?
|
| Histocompatibility Antigens Class II | 10 | 2001 | 1435 | 0.370 |
Why?
|
| Animals, Genetically Modified | 9 | 2024 | 1559 | 0.370 |
Why?
|
| Triage | 1 | 2018 | 985 | 0.370 |
Why?
|
| Rats | 48 | 2023 | 23705 | 0.370 |
Why?
|
| Hepatectomy | 6 | 2020 | 557 | 0.370 |
Why?
|
| Adoptive Transfer | 6 | 2021 | 823 | 0.370 |
Why?
|
| Immune System | 2 | 2013 | 792 | 0.370 |
Why?
|
| Interferon-gamma | 6 | 2013 | 3155 | 0.360 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2014 | 238 | 0.360 |
Why?
|
| Blood Coagulation Factors | 4 | 2017 | 366 | 0.360 |
Why?
|
| Patient Selection | 12 | 2022 | 4246 | 0.350 |
Why?
|
| Nephrectomy | 5 | 2017 | 938 | 0.350 |
Why?
|
| Cold Temperature | 5 | 2021 | 783 | 0.350 |
Why?
|
| Adult | 83 | 2024 | 221120 | 0.350 |
Why?
|
| Kidney Function Tests | 3 | 2024 | 680 | 0.350 |
Why?
|
| Middle Aged | 86 | 2024 | 220858 | 0.350 |
Why?
|
| Donor Selection | 5 | 2023 | 232 | 0.350 |
Why?
|
| Alginates | 4 | 2023 | 248 | 0.350 |
Why?
|
| CD40 Ligand | 4 | 2021 | 524 | 0.350 |
Why?
|
| Sirolimus | 5 | 2022 | 1540 | 0.340 |
Why?
|
| Macaca fascicularis | 5 | 2023 | 901 | 0.340 |
Why?
|
| Vascular System Injuries | 1 | 2013 | 246 | 0.340 |
Why?
|
| Mice, Transgenic | 20 | 2022 | 9520 | 0.340 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 282 | 0.340 |
Why?
|
| Blood Glucose | 20 | 2020 | 6392 | 0.340 |
Why?
|
| Lymphocyte Depletion | 9 | 2006 | 602 | 0.330 |
Why?
|
| Chemokine CXCL12 | 4 | 2023 | 454 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2021 | 5666 | 0.330 |
Why?
|
| Pancreatic Ducts | 3 | 2018 | 329 | 0.330 |
Why?
|
| Health Services Accessibility | 9 | 2018 | 5426 | 0.330 |
Why?
|
| HLA Antigens | 3 | 2012 | 1331 | 0.320 |
Why?
|
| Killer Cells, Natural | 4 | 2017 | 2194 | 0.320 |
Why?
|
| Antigen-Presenting Cells | 8 | 2010 | 965 | 0.320 |
Why?
|
| Immunologic Memory | 2 | 2013 | 1361 | 0.320 |
Why?
|
| Lung Transplantation | 2 | 2017 | 1307 | 0.300 |
Why?
|
| Tissue and Organ Harvesting | 5 | 2019 | 373 | 0.300 |
Why?
|
| Laparoscopy | 3 | 2013 | 2035 | 0.300 |
Why?
|
| Postoperative Complications | 19 | 2017 | 15637 | 0.290 |
Why?
|
| Histocompatibility Antigens Class I | 9 | 2010 | 1348 | 0.290 |
Why?
|
| Female | 99 | 2024 | 392552 | 0.290 |
Why?
|
| Surgery Department, Hospital | 1 | 2008 | 176 | 0.290 |
Why?
|
| Treatment Outcome | 37 | 2021 | 64681 | 0.280 |
Why?
|
| Galactosyltransferases | 3 | 2024 | 276 | 0.280 |
Why?
|
| Melatonin | 1 | 2012 | 668 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 4 | 2022 | 1963 | 0.270 |
Why?
|
| Kidney Diseases | 4 | 2011 | 2092 | 0.270 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 1749 | 0.260 |
Why?
|
| Ablation Techniques | 2 | 2020 | 247 | 0.260 |
Why?
|
| Bone and Bones | 1 | 2017 | 2568 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 9417 | 0.260 |
Why?
|
| Aspergillus fumigatus | 2 | 2019 | 157 | 0.260 |
Why?
|
| Pilot Projects | 5 | 2024 | 8642 | 0.250 |
Why?
|
| Forkhead Transcription Factors | 7 | 2019 | 1613 | 0.250 |
Why?
|
| Papio | 6 | 2018 | 669 | 0.250 |
Why?
|
| Transplantation, Heterotopic | 10 | 2018 | 175 | 0.250 |
Why?
|
| Time Factors | 32 | 2021 | 39957 | 0.240 |
Why?
|
| Rats, Inbred BB | 13 | 1992 | 29 | 0.240 |
Why?
|
| Tissue Survival | 3 | 2019 | 120 | 0.240 |
Why?
|
| Transgenes | 4 | 2023 | 1008 | 0.240 |
Why?
|
| Risk Factors | 23 | 2023 | 74241 | 0.240 |
Why?
|
| Diabetes Mellitus | 8 | 2023 | 5842 | 0.230 |
Why?
|
| Lymphocyte Culture Test, Mixed | 5 | 2021 | 509 | 0.230 |
Why?
|
| Cells, Cultured | 17 | 2022 | 18927 | 0.230 |
Why?
|
| Immunity, Innate | 4 | 2022 | 3044 | 0.230 |
Why?
|
| Mice, Inbred Strains | 6 | 2012 | 1762 | 0.230 |
Why?
|
| Histocompatibility Testing | 7 | 2013 | 716 | 0.230 |
Why?
|
| Mycophenolic Acid | 2 | 2023 | 350 | 0.230 |
Why?
|
| Survival Rate | 18 | 2021 | 12728 | 0.230 |
Why?
|
| Discriminant Analysis | 1 | 2004 | 224 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2014 | 3200 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 2058 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2022 | 7851 | 0.220 |
Why?
|
| Bariatric Surgery | 1 | 2013 | 991 | 0.220 |
Why?
|
| Macaca mulatta | 3 | 2022 | 2328 | 0.210 |
Why?
|
| Economic Competition | 2 | 2016 | 219 | 0.210 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 39127 | 0.210 |
Why?
|
| Raffinose | 2 | 2021 | 53 | 0.210 |
Why?
|
| Regenerative Medicine | 2 | 2017 | 307 | 0.210 |
Why?
|
| Ischemia | 4 | 2020 | 1889 | 0.210 |
Why?
|
| Antibodies | 5 | 2014 | 2415 | 0.200 |
Why?
|
| United States | 27 | 2023 | 72341 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 9278 | 0.200 |
Why?
|
| Cadaver | 7 | 2013 | 1358 | 0.200 |
Why?
|
| Mice, SCID | 8 | 2011 | 2621 | 0.200 |
Why?
|
| Leukocyte Transfusion | 1 | 2001 | 56 | 0.200 |
Why?
|
| Prognosis | 12 | 2024 | 29688 | 0.200 |
Why?
|
| Bile Duct Diseases | 2 | 2017 | 97 | 0.190 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2021 | 24 | 0.190 |
Why?
|
| Lymphocytes | 5 | 2009 | 2603 | 0.190 |
Why?
|
| Antigens, Heterophile | 1 | 2001 | 70 | 0.190 |
Why?
|
| Allopurinol | 2 | 2021 | 198 | 0.190 |
Why?
|
| Hepatitis B | 3 | 2021 | 703 | 0.180 |
Why?
|
| Renin | 1 | 2023 | 639 | 0.180 |
Why?
|
| Dyskeratosis Congenita | 1 | 2021 | 70 | 0.180 |
Why?
|
| Creatinine | 7 | 2008 | 1897 | 0.180 |
Why?
|
| Rats, Inbred WF | 15 | 1993 | 140 | 0.180 |
Why?
|
| Pancreas | 5 | 2018 | 1684 | 0.180 |
Why?
|
| Liver Function Tests | 7 | 2020 | 525 | 0.180 |
Why?
|
| Health Care Rationing | 2 | 2016 | 435 | 0.180 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 2 | 2010 | 39 | 0.170 |
Why?
|
| Interleukin-10 | 3 | 2013 | 1176 | 0.170 |
Why?
|
| Glutathione | 2 | 2021 | 581 | 0.170 |
Why?
|
| Commerce | 2 | 2016 | 608 | 0.170 |
Why?
|
| C-Peptide | 6 | 2018 | 442 | 0.170 |
Why?
|
| Hypoglycemia | 5 | 2018 | 883 | 0.170 |
Why?
|
| Tumor Necrosis Factors | 2 | 2010 | 109 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 415 | 0.170 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 132 | 0.170 |
Why?
|
| Mice, Inbred NOD | 8 | 2022 | 1822 | 0.170 |
Why?
|
| Aged | 32 | 2023 | 169292 | 0.170 |
Why?
|
| Liver Regeneration | 2 | 2018 | 214 | 0.170 |
Why?
|
| Blood Cells | 1 | 2021 | 306 | 0.170 |
Why?
|
| Expert Testimony | 1 | 2022 | 365 | 0.170 |
Why?
|
| Renal Insufficiency | 4 | 2017 | 808 | 0.160 |
Why?
|
| Sus scrofa | 1 | 2020 | 428 | 0.160 |
Why?
|
| Proportional Hazards Models | 14 | 2018 | 12474 | 0.160 |
Why?
|
| Aging | 4 | 2013 | 8702 | 0.160 |
Why?
|
| Genetic Engineering | 3 | 2020 | 930 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 1027 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2022 | 577 | 0.160 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 181 | 0.160 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2021 | 897 | 0.160 |
Why?
|
| beta 2-Microglobulin | 3 | 1994 | 329 | 0.160 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 1600 | 0.160 |
Why?
|
| Deoxyglucose | 1 | 2019 | 333 | 0.150 |
Why?
|
| Liver Cirrhosis | 3 | 2018 | 1932 | 0.150 |
Why?
|
| Survival Analysis | 10 | 2020 | 10088 | 0.150 |
Why?
|
| Risk Assessment | 11 | 2021 | 24022 | 0.150 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 1432 | 0.150 |
Why?
|
| Aspergillosis | 2 | 2019 | 242 | 0.150 |
Why?
|
| Immunity, Cellular | 5 | 2015 | 1553 | 0.150 |
Why?
|
| Steroids | 1 | 2023 | 929 | 0.150 |
Why?
|
| Homeostasis | 4 | 2022 | 3322 | 0.150 |
Why?
|
| Nephritis, Interstitial | 1 | 2019 | 155 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2024 | 863 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2018 | 92 | 0.150 |
Why?
|
| Adenosine | 2 | 2021 | 805 | 0.150 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 585 | 0.140 |
Why?
|
| Healthcare Disparities | 5 | 2016 | 3354 | 0.140 |
Why?
|
| Coculture Techniques | 1 | 2021 | 1334 | 0.140 |
Why?
|
| Adenine Nucleotides | 1 | 2017 | 110 | 0.140 |
Why?
|
| Kidney Tubules | 1 | 2019 | 448 | 0.140 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 12052 | 0.140 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 145 | 0.140 |
Why?
|
| Registries | 7 | 2016 | 8246 | 0.140 |
Why?
|
| Porosity | 1 | 2018 | 348 | 0.140 |
Why?
|
| Thrombocytopenia | 2 | 2016 | 1182 | 0.140 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2017 | 24 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2017 | 297 | 0.140 |
Why?
|
| Renal Dialysis | 6 | 2017 | 1796 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2003 | 947 | 0.140 |
Why?
|
| Genetic Vectors | 4 | 2004 | 3388 | 0.140 |
Why?
|
| Age Factors | 7 | 2016 | 18384 | 0.140 |
Why?
|
| Oxalates | 1 | 2017 | 98 | 0.140 |
Why?
|
| Swine, Miniature | 4 | 2023 | 961 | 0.140 |
Why?
|
| Gene Transfer Techniques | 4 | 2003 | 1201 | 0.140 |
Why?
|
| Models, Animal | 4 | 2020 | 2114 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2005 | 1160 | 0.140 |
Why?
|
| Regeneration | 4 | 2016 | 1505 | 0.140 |
Why?
|
| Length of Stay | 4 | 2016 | 6417 | 0.130 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 137 | 0.130 |
Why?
|
| Germ Cells | 1 | 2020 | 632 | 0.130 |
Why?
|
| Glucagon | 4 | 2008 | 531 | 0.130 |
Why?
|
| Social Class | 2 | 2016 | 1993 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2008 | 2549 | 0.130 |
Why?
|
| Organ Culture Techniques | 2 | 2017 | 792 | 0.130 |
Why?
|
| Competitive Medical Plans | 1 | 2016 | 26 | 0.130 |
Why?
|
| Immunization, Passive | 4 | 1998 | 617 | 0.130 |
Why?
|
| Elastic Modulus | 1 | 2017 | 211 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2024 | 4574 | 0.130 |
Why?
|
| Oxygen Consumption | 2 | 2019 | 1867 | 0.130 |
Why?
|
| Lac Operon | 4 | 2003 | 237 | 0.130 |
Why?
|
| Hepatocytes | 3 | 2020 | 1230 | 0.130 |
Why?
|
| Hypothermia, Induced | 2 | 2020 | 754 | 0.130 |
Why?
|
| Recombinant Proteins | 5 | 2018 | 6504 | 0.130 |
Why?
|
| Mice, Inbred DBA | 5 | 1995 | 623 | 0.130 |
Why?
|
| Neuroaspergillosis | 1 | 2015 | 2 | 0.120 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2015 | 221 | 0.120 |
Why?
|
| Resuscitation | 1 | 2020 | 672 | 0.120 |
Why?
|
| Autoimmune Diseases | 9 | 2010 | 2244 | 0.120 |
Why?
|
| Streptozocin | 2 | 2015 | 193 | 0.120 |
Why?
|
| Jaundice, Obstructive | 1 | 2015 | 21 | 0.120 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2015 | 24 | 0.120 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 497 | 0.120 |
Why?
|
| Interleukin-2 | 5 | 2011 | 1891 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2006 | 3461 | 0.120 |
Why?
|
| Cell Transplantation | 1 | 2017 | 472 | 0.120 |
Why?
|
| Congresses as Topic | 2 | 2018 | 803 | 0.120 |
Why?
|
| Recovery of Function | 3 | 2008 | 2981 | 0.120 |
Why?
|
| Contrast Media | 3 | 2015 | 5311 | 0.120 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 197 | 0.120 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 307 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 1662 | 0.120 |
Why?
|
| Antigens, CD | 3 | 2021 | 4009 | 0.120 |
Why?
|
| Models, Theoretical | 2 | 2004 | 3571 | 0.120 |
Why?
|
| Neutrophils | 2 | 2019 | 3763 | 0.120 |
Why?
|
| Recurrence | 8 | 2023 | 8457 | 0.120 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 15308 | 0.120 |
Why?
|
| Telephone | 1 | 2018 | 624 | 0.120 |
Why?
|
| Dextrans | 2 | 2015 | 574 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2019 | 6486 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2021 | 1741 | 0.120 |
Why?
|
| Genes, MHC Class II | 2 | 1997 | 433 | 0.110 |
Why?
|
| Gene Knockout Techniques | 3 | 2024 | 801 | 0.110 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2014 | 49 | 0.110 |
Why?
|
| Health Care Sector | 1 | 2016 | 195 | 0.110 |
Why?
|
| Cell Separation | 8 | 2020 | 1721 | 0.110 |
Why?
|
| Liver Circulation | 1 | 2014 | 159 | 0.110 |
Why?
|
| Endocrine Glands | 1 | 2013 | 101 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2008 | 4321 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2020 | 789 | 0.110 |
Why?
|
| Genes, MHC Class I | 1 | 1994 | 235 | 0.110 |
Why?
|
| Fluorocarbons | 1 | 2019 | 492 | 0.110 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 1385 | 0.110 |
Why?
|
| History, 16th Century | 1 | 2013 | 70 | 0.110 |
Why?
|
| Cell Differentiation | 5 | 2018 | 11512 | 0.110 |
Why?
|
| Cytokines | 9 | 2023 | 7386 | 0.110 |
Why?
|
| Immunophenotyping | 3 | 2013 | 1867 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1997 | 548 | 0.110 |
Why?
|
| Research Report | 1 | 2016 | 367 | 0.110 |
Why?
|
| Crosses, Genetic | 2 | 2009 | 752 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2021 | 3777 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 660 | 0.100 |
Why?
|
| History, Ancient | 1 | 2013 | 213 | 0.100 |
Why?
|
| Medically Underserved Area | 1 | 2015 | 254 | 0.100 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2012 | 222 | 0.100 |
Why?
|
| Cell Proliferation | 6 | 2019 | 10423 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 3 | 2017 | 2182 | 0.100 |
Why?
|
| Lymphoid Tissue | 2 | 1993 | 445 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 1923 | 0.100 |
Why?
|
| Protein S Deficiency | 1 | 2011 | 13 | 0.100 |
Why?
|
| Fatal Outcome | 3 | 2016 | 1838 | 0.100 |
Why?
|
| Stem Cells | 3 | 2021 | 3517 | 0.100 |
Why?
|
| Constriction, Pathologic | 3 | 2011 | 1097 | 0.100 |
Why?
|
| Pluripotent Stem Cells | 2 | 2018 | 794 | 0.100 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2011 | 32 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 3726 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2016 | 489 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2022 | 23419 | 0.100 |
Why?
|
| Biological Products | 1 | 2021 | 915 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 2015 | 1250 | 0.100 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 724 | 0.090 |
Why?
|
| Quality of Life | 3 | 2022 | 13367 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 6304 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 598 | 0.090 |
Why?
|
| Cholestasis | 1 | 2014 | 378 | 0.090 |
Why?
|
| Heart Arrest | 2 | 2016 | 1513 | 0.090 |
Why?
|
| Species Specificity | 5 | 2004 | 2406 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2016 | 970 | 0.090 |
Why?
|
| Adenovirus Infections, Human | 1 | 2011 | 73 | 0.090 |
Why?
|
| Receptors, CCR2 | 1 | 2011 | 214 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2019 | 1330 | 0.090 |
Why?
|
| Endocrine System | 1 | 2011 | 113 | 0.090 |
Why?
|
| Metabolomics | 1 | 2020 | 1658 | 0.090 |
Why?
|
| Microfluidics | 1 | 2015 | 651 | 0.090 |
Why?
|
| Bile Ducts | 1 | 2011 | 284 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2024 | 54437 | 0.090 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2112 | 0.090 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 1273 | 0.090 |
Why?
|
| Patient Readmission | 3 | 2016 | 3265 | 0.090 |
Why?
|
| Gene Expression Regulation | 4 | 2022 | 11855 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 501 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2015 | 752 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2019 | 2413 | 0.080 |
Why?
|
| Cysts | 1 | 2015 | 680 | 0.080 |
Why?
|
| Antibody Formation | 5 | 1997 | 1391 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 823 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2012 | 771 | 0.080 |
Why?
|
| Thrombosis | 1 | 2023 | 2944 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 294 | 0.080 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 18222 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2017 | 1375 | 0.080 |
Why?
|
| Autopsy | 1 | 2013 | 1010 | 0.080 |
Why?
|
| Metabolome | 1 | 2016 | 989 | 0.080 |
Why?
|
| Terminology as Topic | 1 | 2016 | 1528 | 0.080 |
Why?
|
| Acute Disease | 3 | 2015 | 7226 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 1994 | 1251 | 0.080 |
Why?
|
| Binding, Competitive | 1 | 2010 | 1140 | 0.080 |
Why?
|
| von Willebrand Factor | 1 | 2012 | 677 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2014 | 1071 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 412 | 0.080 |
Why?
|
| Geography | 3 | 2016 | 652 | 0.080 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2008 | 42 | 0.080 |
Why?
|
| Flow Cytometry | 5 | 2013 | 5871 | 0.080 |
Why?
|
| Mice, Knockout | 6 | 2022 | 14392 | 0.080 |
Why?
|
| Health Resources | 2 | 2004 | 934 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2023 | 15841 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 991 | 0.070 |
Why?
|
| Biliary Tract Diseases | 2 | 2011 | 158 | 0.070 |
Why?
|
| Heart-Assist Devices | 2 | 2014 | 1288 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 2223 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2018 | 3923 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2014 | 1303 | 0.070 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2015 | 506 | 0.070 |
Why?
|
| Glucose | 4 | 2020 | 4342 | 0.070 |
Why?
|
| Proinsulin | 2 | 2008 | 135 | 0.070 |
Why?
|
| Delayed Graft Function | 2 | 2022 | 53 | 0.070 |
Why?
|
| Gene Expression | 3 | 1997 | 7571 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36415 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 1662 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 6819 | 0.070 |
Why?
|
| Chemokine CCL5 | 2 | 2019 | 214 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 2067 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 2 | 2006 | 413 | 0.070 |
Why?
|
| Phlebography | 1 | 2008 | 326 | 0.070 |
Why?
|
| Heart | 2 | 2019 | 4431 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2019 | 3048 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2013 | 1567 | 0.070 |
Why?
|
| Interleukins | 1 | 2011 | 782 | 0.070 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2008 | 335 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1304 | 0.070 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 379 | 0.070 |
Why?
|
| Papio hamadryas | 2 | 2017 | 31 | 0.070 |
Why?
|
| Child | 11 | 2022 | 80154 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 1995 | 1783 | 0.070 |
Why?
|
| Inflammation | 3 | 2011 | 10759 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2017 | 2877 | 0.070 |
Why?
|
| Cohort Studies | 8 | 2016 | 41496 | 0.070 |
Why?
|
| Incidence | 5 | 2016 | 21366 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2008 | 364 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2023 | 3552 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 2004 | 0.060 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2006 | 53 | 0.060 |
Why?
|
| Hepatic Insufficiency | 1 | 2005 | 14 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2015 | 1545 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2019 | 12747 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2017 | 3390 | 0.060 |
Why?
|
| Glucokinase | 1 | 2006 | 102 | 0.060 |
Why?
|
| Adenoviruses, Human | 2 | 1999 | 255 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2021 | 1664 | 0.060 |
Why?
|
| Pennsylvania | 2 | 2009 | 612 | 0.060 |
Why?
|
| Organ Size | 2 | 2015 | 2253 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2011 | 1495 | 0.060 |
Why?
|
| Prediabetic State | 2 | 1988 | 546 | 0.060 |
Why?
|
| Myxoma | 1 | 2005 | 114 | 0.060 |
Why?
|
| Arm | 1 | 2008 | 589 | 0.060 |
Why?
|
| Fistula | 1 | 2006 | 212 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2013 | 2765 | 0.060 |
Why?
|
| Injections | 2 | 2001 | 832 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 290 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 1141 | 0.060 |
Why?
|
| Thymectomy | 3 | 2011 | 195 | 0.060 |
Why?
|
| Cyclosporins | 3 | 1989 | 216 | 0.060 |
Why?
|
| Microscopy, Electron | 2 | 2003 | 2561 | 0.060 |
Why?
|
| Spleen | 5 | 2015 | 2290 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2020 | 1892 | 0.060 |
Why?
|
| Leucine | 1 | 2006 | 546 | 0.060 |
Why?
|
| Minor Lymphocyte Stimulatory Antigens | 2 | 1994 | 10 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 1128 | 0.060 |
Why?
|
| Intracranial Embolism | 1 | 2005 | 189 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2005 | 355 | 0.060 |
Why?
|
| Adolescent | 14 | 2018 | 88300 | 0.060 |
Why?
|
| Portal System | 1 | 2003 | 49 | 0.060 |
Why?
|
| Angioplasty | 1 | 2006 | 356 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2016 | 3422 | 0.060 |
Why?
|
| Immunization | 2 | 2006 | 1218 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 12159 | 0.050 |
Why?
|
| Injections, Intralymphatic | 1 | 2003 | 15 | 0.050 |
Why?
|
| Ureteral Diseases | 1 | 2003 | 63 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 531 | 0.050 |
Why?
|
| Hypoglycemic Agents | 3 | 2018 | 3089 | 0.050 |
Why?
|
| Epitopes | 1 | 2009 | 2504 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2007 | 1818 | 0.050 |
Why?
|
| Forelimb | 1 | 2023 | 116 | 0.050 |
Why?
|
| Databases, Factual | 4 | 2017 | 7965 | 0.050 |
Why?
|
| Hospitals, University | 3 | 1999 | 565 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2010 | 963 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2018 | 3758 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 359 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3412 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 1997 | 1751 | 0.050 |
Why?
|
| Streptavidin | 1 | 2022 | 81 | 0.050 |
Why?
|
| Kidney Pelvis | 1 | 2003 | 186 | 0.050 |
Why?
|
| International Cooperation | 2 | 2019 | 1423 | 0.050 |
Why?
|
| Radiography | 3 | 2015 | 6974 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 524 | 0.050 |
Why?
|
| Omentum | 1 | 2023 | 167 | 0.050 |
Why?
|
| Bile | 1 | 2003 | 297 | 0.050 |
Why?
|
| Young Adult | 9 | 2021 | 59222 | 0.050 |
Why?
|
| Macrophages | 2 | 2020 | 5755 | 0.050 |
Why?
|
| Biopsy | 4 | 2019 | 6781 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 237 | 0.050 |
Why?
|
| Calcineurin | 1 | 2002 | 229 | 0.050 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2003 | 158 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 1 | 2004 | 353 | 0.050 |
Why?
|
| Equipment Design | 2 | 2020 | 3510 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2011 | 2159 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10218 | 0.050 |
Why?
|
| Capsules | 1 | 2021 | 191 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2003 | 6345 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2003 | 293 | 0.050 |
Why?
|
| Alkaline Phosphatase | 2 | 2011 | 859 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 918 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2008 | 1316 | 0.050 |
Why?
|
| Cause of Death | 3 | 2017 | 3688 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2023 | 344 | 0.050 |
Why?
|
| Pancreatectomy | 1 | 2005 | 811 | 0.050 |
Why?
|
| Lentivirus | 1 | 2004 | 508 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2004 | 900 | 0.050 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2020 | 61 | 0.050 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 99 | 0.040 |
Why?
|
| Hepatitis B virus | 2 | 2021 | 527 | 0.040 |
Why?
|
| Hemostasis | 1 | 2023 | 470 | 0.040 |
Why?
|
| Hemodynamics | 3 | 2020 | 4165 | 0.040 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2020 | 63 | 0.040 |
Why?
|
| Dendritic Cells | 2 | 2022 | 2726 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2016 | 3434 | 0.040 |
Why?
|
| Graft Enhancement, Immunologic | 3 | 1990 | 58 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2003 | 298 | 0.040 |
Why?
|
| Boston | 3 | 2018 | 9327 | 0.040 |
Why?
|
| Reference Values | 2 | 2005 | 4921 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1994 | 800 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2006 | 1264 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3418 | 0.040 |
Why?
|
| Cell Communication | 1 | 2007 | 1651 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2011 | 1959 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2004 | 3239 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 3702 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 50 | 0.040 |
Why?
|
| Postoperative Care | 2 | 2004 | 1468 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2021 | 3114 | 0.040 |
Why?
|
| Ice | 1 | 2020 | 102 | 0.040 |
Why?
|
| Freezing | 1 | 2020 | 311 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2020 | 265 | 0.040 |
Why?
|
| Caspases | 1 | 2022 | 878 | 0.040 |
Why?
|
| Rewarming | 1 | 2019 | 64 | 0.040 |
Why?
|
| Culture Techniques | 3 | 1989 | 530 | 0.040 |
Why?
|
| Reassortant Viruses | 1 | 1999 | 36 | 0.040 |
Why?
|
| Cryoprotective Agents | 1 | 2020 | 128 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 2827 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 10756 | 0.040 |
Why?
|
| Monocytes | 2 | 2023 | 2570 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2003 | 822 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2024 | 891 | 0.040 |
Why?
|
| Hepatic Stellate Cells | 1 | 2020 | 119 | 0.040 |
Why?
|
| Models, Biological | 2 | 2014 | 9458 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 13249 | 0.040 |
Why?
|
| Kinetics | 2 | 2019 | 6312 | 0.040 |
Why?
|
| Appendicitis | 1 | 2005 | 676 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2010 | 2054 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2024 | 951 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2022 | 1644 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 982 | 0.040 |
Why?
|
| Jejunoileal Bypass | 1 | 1998 | 13 | 0.040 |
Why?
|
| Artificial Organs | 1 | 2000 | 149 | 0.040 |
Why?
|
| Probability | 1 | 2004 | 2478 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2021 | 737 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2003 | 703 | 0.040 |
Why?
|
| Integrin alphaV | 1 | 2018 | 54 | 0.040 |
Why?
|
| Rats, Inbred BN | 4 | 1991 | 231 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2008 | 1425 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 261 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2018 | 223 | 0.040 |
Why?
|
| Aneurysm, Infected | 1 | 1998 | 82 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2023 | 658 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 1997 | 2665 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 394 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 339 | 0.040 |
Why?
|
| Forecasting | 2 | 2017 | 2928 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2015 | 5081 | 0.040 |
Why?
|
| Mice, Inbred CBA | 2 | 1995 | 438 | 0.040 |
Why?
|
| Hemopneumothorax | 1 | 1997 | 5 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 296 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2003 | 1179 | 0.040 |
Why?
|
| Cell Survival | 3 | 2010 | 5778 | 0.040 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 1997 | 62 | 0.040 |
Why?
|
| Hyperoxaluria | 1 | 2017 | 32 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2021 | 5250 | 0.030 |
Why?
|
| Hemothorax | 1 | 1997 | 58 | 0.030 |
Why?
|
| Lamivudine | 1 | 1998 | 366 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2023 | 1014 | 0.030 |
Why?
|
| Age of Onset | 1 | 2004 | 3307 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2020 | 933 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 2017 | 174 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2021 | 1963 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 12976 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1991 | 1351 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 4 | 2015 | 2692 | 0.030 |
Why?
|
| Mitosis | 1 | 2001 | 1187 | 0.030 |
Why?
|
| Pneumothorax | 2 | 1997 | 386 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1997 | 864 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2016 | 2643 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 574 | 0.030 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 2087 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 20588 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 1784 | 0.030 |
Why?
|
| Viral Envelope Proteins | 2 | 2013 | 639 | 0.030 |
Why?
|
| Aspergillus flavus | 1 | 2015 | 14 | 0.030 |
Why?
|
| Scedosporium | 1 | 2015 | 10 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2019 | 1636 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 145 | 0.030 |
Why?
|
| Gastroenterology | 1 | 2021 | 580 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 150 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1998 | 621 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1376 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 628 | 0.030 |
Why?
|
| California | 1 | 1999 | 1431 | 0.030 |
Why?
|
| Aspergillus | 1 | 2015 | 94 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 8164 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2022 | 4567 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1791 | 0.030 |
Why?
|
| Disease Progression | 4 | 2020 | 13511 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 309 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2018 | 3671 | 0.030 |
Why?
|
| Atrophy | 1 | 2019 | 1633 | 0.030 |
Why?
|
| Arginine | 2 | 2008 | 920 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2016 | 9652 | 0.030 |
Why?
|
| Thoracic Injuries | 1 | 1997 | 289 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 11067 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 858 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2018 | 42225 | 0.030 |
Why?
|
| HeLa Cells | 2 | 1997 | 3073 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 14675 | 0.030 |
Why?
|
| Receptors, CCR6 | 1 | 2014 | 74 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 410 | 0.030 |
Why?
|
| Chimera | 2 | 1993 | 453 | 0.030 |
Why?
|
| Microspheres | 1 | 2017 | 783 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2019 | 1334 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 2227 | 0.030 |
Why?
|
| H-Y Antigen | 1 | 1993 | 42 | 0.030 |
Why?
|
| Magnetite Nanoparticles | 1 | 2015 | 316 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 1225 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 2138 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 411 | 0.030 |
Why?
|
| Biliary Tract | 1 | 2014 | 135 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1624 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2000 | 828 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 2 | 1993 | 1468 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1999 | 2928 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 2048 | 0.030 |
Why?
|
| Aurintricarboxylic Acid | 1 | 2012 | 10 | 0.030 |
Why?
|
| Gastrins | 1 | 2013 | 75 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2014 | 238 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 281 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2018 | 22174 | 0.030 |
Why?
|
| Immunotherapy | 2 | 1988 | 4642 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2016 | 544 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 793 | 0.030 |
Why?
|
| Apoptosis | 2 | 2011 | 9478 | 0.030 |
Why?
|
| Venoms | 1 | 2013 | 94 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 3163 | 0.030 |
Why?
|
| North America | 1 | 2016 | 1284 | 0.030 |
Why?
|
| Phenotype | 4 | 2016 | 16575 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1998 | 1207 | 0.020 |
Why?
|
| Protein S | 1 | 2011 | 29 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 602 | 0.020 |
Why?
|
| Complement Activation | 1 | 1994 | 445 | 0.020 |
Why?
|
| Massachusetts | 2 | 2016 | 8837 | 0.020 |
Why?
|
| Fibrosis | 1 | 2019 | 2052 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2016 | 1046 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2020 | 1807 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2012 | 286 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 4340 | 0.020 |
Why?
|
| Organoids | 1 | 2018 | 744 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 5773 | 0.020 |
Why?
|
| Castration | 1 | 2011 | 150 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2011 | 65 | 0.020 |
Why?
|
| Gonads | 1 | 2011 | 109 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 1381 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1998 | 1116 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3423 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 4251 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2015 | 432 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 730 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1893 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 126 | 0.020 |
Why?
|
| Disease Management | 1 | 2021 | 2507 | 0.020 |
Why?
|
| Cell Movement | 1 | 2003 | 5195 | 0.020 |
Why?
|
| Peptides | 2 | 2013 | 4353 | 0.020 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 345 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2011 | 302 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 1991 | 312 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 362 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1997 | 3606 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2002 | 1923 | 0.020 |
Why?
|
| Plasmids | 1 | 1995 | 2261 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1999 | 2468 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 245 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 5145 | 0.020 |
Why?
|
| Neck | 1 | 1995 | 734 | 0.020 |
Why?
|
| Rabbits | 1 | 2016 | 4750 | 0.020 |
Why?
|
| Antigens | 1 | 2015 | 1441 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 699 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2016 | 1141 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2012 | 578 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 736 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2018 | 26200 | 0.020 |
Why?
|
| Bilirubin | 1 | 2011 | 436 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1977 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2014 | 799 | 0.020 |
Why?
|
| Leuprolide | 1 | 2011 | 312 | 0.020 |
Why?
|
| Triazoles | 1 | 2015 | 902 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1989 | 212 | 0.020 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2011 | 172 | 0.020 |
Why?
|
| Epithelium | 1 | 2014 | 1603 | 0.020 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2015 | 799 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2004 | 9319 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2014 | 1042 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 2897 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 410 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2010 | 671 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 3134 | 0.020 |
Why?
|
| Haplotypes | 1 | 1995 | 2715 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1885 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2015 | 794 | 0.020 |
Why?
|
| G(M1) Ganglioside | 1 | 1988 | 87 | 0.020 |
Why?
|
| Mitochondria | 1 | 2021 | 3620 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2008 | 111 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2010 | 725 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 1401 | 0.020 |
Why?
|
| Glycosphingolipids | 1 | 1988 | 73 | 0.020 |
Why?
|
| Immune Sera | 1 | 1988 | 605 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2011 | 911 | 0.020 |
Why?
|
| Infant | 3 | 2018 | 36170 | 0.020 |
Why?
|
| Sex Factors | 2 | 2016 | 10553 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2016 | 2489 | 0.020 |
Why?
|
| Zebrafish | 1 | 2019 | 3000 | 0.020 |
Why?
|
| Cell Division | 2 | 2010 | 4451 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 2410 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1987 | 116 | 0.020 |
Why?
|
| Data Collection | 1 | 2016 | 3320 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 1525 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2006 | 262 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 1676 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 381 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2004 | 12952 | 0.020 |
Why?
|
| Prednisolone | 1 | 2007 | 324 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2011 | 951 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2016 | 2092 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 1812 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1789 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 11119 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8519 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 3453 | 0.020 |
Why?
|
| beta Catenin | 1 | 2010 | 1042 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2007 | 1059 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2008 | 2241 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2005 | 384 | 0.010 |
Why?
|
| NADP | 1 | 2006 | 227 | 0.010 |
Why?
|
| Vincristine | 1 | 2007 | 1036 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2013 | 2839 | 0.010 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2015 | 1645 | 0.010 |
Why?
|
| Aviation | 1 | 2004 | 49 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 96 | 0.010 |
Why?
|
| Risk | 1 | 2016 | 9616 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 694 | 0.010 |
Why?
|
| Veins | 1 | 2008 | 767 | 0.010 |
Why?
|
| Intestinal Perforation | 1 | 2005 | 249 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 103 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1995 | 3111 | 0.010 |
Why?
|
| Universities | 1 | 2009 | 995 | 0.010 |
Why?
|
| Epinephrine | 1 | 2006 | 791 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3803 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1900 | 0.010 |
Why?
|
| Dimerization | 1 | 2005 | 887 | 0.010 |
Why?
|
| Stents | 1 | 2015 | 3177 | 0.010 |
Why?
|
| Fetus | 1 | 1990 | 1864 | 0.010 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2004 | 176 | 0.010 |
Why?
|
| Insulinoma | 1 | 2003 | 121 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 1520 | 0.010 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2003 | 76 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2011 | 2119 | 0.010 |
Why?
|
| Transportation | 1 | 2004 | 217 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 273 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 613 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14610 | 0.010 |
Why?
|
| Appendectomy | 1 | 2005 | 434 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1994 | 317 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 2006 | 642 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2005 | 1178 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1988 | 1408 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2219 | 0.010 |
Why?
|
| Cell Line | 2 | 1996 | 15545 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 1168 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2007 | 2224 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 2392 | 0.010 |
Why?
|
| Heart Atria | 1 | 2005 | 1349 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8300 | 0.010 |
Why?
|
| Obesity | 1 | 2021 | 12940 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2005 | 1067 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 8998 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2013 | 12341 | 0.010 |
Why?
|
| Vascular Fistula | 1 | 1998 | 50 | 0.010 |
Why?
|
| Ileal Diseases | 1 | 1998 | 68 | 0.010 |
Why?
|
| Philadelphia | 1 | 1999 | 267 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 58952 | 0.010 |
Why?
|
| Genotype | 1 | 2013 | 12985 | 0.010 |
Why?
|
| Los Angeles | 1 | 1998 | 244 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2003 | 1516 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 3590 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1999 | 697 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1998 | 142 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 372 | 0.010 |
Why?
|
| Auscultation | 1 | 1997 | 38 | 0.010 |
Why?
|
| Energy Intake | 1 | 2005 | 2133 | 0.010 |
Why?
|
| Linear Models | 1 | 2007 | 5869 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6125 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 14025 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1998 | 625 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2011 | 3407 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1998 | 850 | 0.010 |
Why?
|
| Brain | 1 | 2022 | 27094 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20118 | 0.010 |
Why?
|
| Wounds, Penetrating | 1 | 1997 | 314 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3696 | 0.010 |
Why?
|
| Safety | 1 | 1997 | 1151 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 5719 | 0.010 |
Why?
|
| Proteomics | 1 | 2006 | 3840 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1998 | 735 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1998 | 876 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 1998 | 1472 | 0.010 |
Why?
|
| Dogs | 1 | 1997 | 3832 | 0.010 |
Why?
|
| Lymphokines | 1 | 1994 | 925 | 0.010 |
Why?
|
| Wounds, Gunshot | 1 | 1997 | 582 | 0.010 |
Why?
|
| Neoplasms | 1 | 2000 | 22142 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 11476 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 2426 | 0.010 |
Why?
|
| Genomics | 1 | 2006 | 5829 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1997 | 1265 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 1999 | 1862 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1993 | 976 | 0.000 |
Why?
|
| Subrenal Capsule Assay | 1 | 1987 | 27 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 7407 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11733 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 5366 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 3149 | 0.000 |
Why?
|
| Rats, Inbred ACI | 1 | 1983 | 34 | 0.000 |
Why?
|
| Thoracic Duct | 1 | 1983 | 64 | 0.000 |
Why?
|
| Concanavalin A | 1 | 1982 | 190 | 0.000 |
Why?
|
| Lung | 1 | 1997 | 9979 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1982 | 1597 | 0.000 |
Why?
|